Skip to main content

Advertisement

Table 3 Crude and adjusted associations of myocardial delayed enhancement with DAS28

From: Assessment of myocardial abnormalities in rheumatoid arthritis using a comprehensive cardiac magnetic resonance approach: a pilot study

Characteristic Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
  β P β P β P β P β P β P
Delayed enhancement* 1.32 0.018 1.82 0.002 1.89 0.004 1.78 0.003 1.71 0.005 1.88 0.002
Male gender*    1.36 0.031 1.39 0.036 1.48 0.036 1.47 0.029 1.78 0.042
Age, per year**      -0.01 0.74       
RA duration, per year**        0.02 0.64     
TNF inhibitor use*          -0.36 0.49   
Framingham risk score, per%            -0.07 0.45
R2 (†) 0.31 0.49 0.50 0.50 0.51 0.51
  1. * β coefficients represent the average change in the outcome (DAS28) for those with the characteristic vs. those without.
  2. ** β coefficients represent the average change in the outcome (DAS28) per 1 unit increase in the characteristic.
  3. † R2 is the percentage of the total variability in the outcome explained by the aggregate of the predictors in the model.